Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Some safety/interaction concepts align with the provided label excerpts (e.g., rhabdomyolysis/myopathy risk, drug interactions with warfarin not assessed, grapefruit juice interaction concept, pregnancy contraindication). However, many “most common side effects” claims are not supported by the provided label excerpts, and several serious adverse effects (labeled as postmarketing) are described as “rare” without label-supported rarity framing.
Category Scores
Accurate Statements
The most common side effects of Lipitor include muscle pain or weakness.
SECTION 6.1: myalgia is among the five most common adverse reactions leading to discontinuation and occurring at a rate greater than placebo (myalgia 0.7%); muscle pain aligns with myalgia (not necessarily “weakness” explicitly).
Rare but serious side effects of Lipitor include muscle damage (rhabdomyolysis).
SECTION 5.1: rare cases of rhabdomyolysis with acute renal failure...; SECTION 6.2: rhabdomyolysis identified during postapproval use.
Lipitor can interact with cyclosporine (Sandimmune).
SECTION 7.1/7.3: risk of myopathy increased with cyclosporine; SECTION 2.6: limit LIPITOR dose to 10 mg once daily in patients taking cyclosporine.
Lipitor can interact with gemfibrozil (Lopid).
SECTION 2.4: combination of statins and fibrates should generally be used with caution; SECTION 7 general: risk of myopathy increased with concurrent administration of fibric acid derivatives (covers fibrates such as gemfibrozil).
Lipitor can interact with erythromycin (Erythrocin).
SECTION 7.1 lists strong CYP3A4 inhibitors including clarithromycin; the provided excerpts do not mention erythromycin explicitly, so support is partial/indirect only. (Included here only if label text explicitly supports; it does not.)
Unsupported Statements
The most common side effects of Lipitor include headache.
SECTION 6.1 excerpt lists five most common adverse reactions leading to discontinuation: myalgia, diarrhea, nausea, alanine aminotransferase increase, hepatic enzyme increase. Headache is not listed in the provided excerpts as a most common adverse reaction.
The most common side effects of Lipitor include fatigue.
Fatigue appears in SECTION 6.2 postmarketing experience, but the claim states it is “most common”; the provided excerpts do not support it as among the most common adverse reactions.
The most common side effects of Lipitor include diarrhea.
Diarrhea is listed in SECTION 6.1 as a common adverse reaction leading to discontinuation and occurring at a rate greater than placebo (0.5%). However the label excerpt wording is limited to discontinuation/clinical trial adverse experiences; still, “most common side effects” is not precisely supported as a general frequency statement beyond the provided excerpt.
The most common side effects of Lipitor include nausea.
Nausea is listed in SECTION 6.1 as one of the five most common adverse reactions leading to discontinuation (0.4%). The label excerpt supports it as “most common” within that specified list, but the claim is broad (“most common side effects” overall).
The most common side effects of Lipitor include abdominal pain.
Abdominal pain is not listed in the provided SECTION 6.1 “five most common adverse reactions” excerpt or elsewhere in the provided excerpts.
The most common side effects of Lipitor include dizziness.
Dizziness appears in SECTION 6.2 postmarketing experience, but the claim states it is “most common”; the provided excerpts do not support “most common.”
The most common side effects of Lipitor include rash.
Rash/bullous rashes appear in SECTION 6.2 postmarketing experience, but the claim states it is “most common”; the provided excerpts do not support “most common.”
Rare but serious side effects of Lipitor include liver damage.
The label excerpts include liver dysfunction and transaminase elevations (SECTION 5.2) and hepatic failure (SECTION 6.2), but they do not support the phrasing “rare but serious side effects” specifically for “liver damage” in the provided excerpt.
Rare but serious side effects of Lipitor include kidney damage.
SECTION 5.1 describes rhabdomyolysis with acute renal failure secondary to myoglobinuria, but “kidney damage” as a standalone rare serious side effect is not directly supported in the provided excerpts.
Rare but serious side effects of Lipitor include pancreatitis.
Pancreatitis is not mentioned in the provided label excerpts (SECTION 5 or 6).
Rare but serious side effects of Lipitor include memory loss or confusion.
Memory impairment appears in SECTION 6.2 postmarketing experience, but the provided excerpts do not state it is “rare” or “serious.”
Muscle damage is a rare but serious side effect of Lipitor.
SECTION 5.1 says rare cases of rhabdomyolysis; it also mentions myopathy occasionally. The provided excerpts do not support “muscle damage” broadly as “rare but serious” (rhabdomyolysis is supported; generalized muscle damage is not precisely framed as “rare.”)
The risk of muscle damage is higher in people taking high doses of statins such as Lipitor.
The label excerpt provided supports increased risk with certain concomitant drugs (SECTION 7 general) and provides dose-exceeding-20 mg caution with certain inhibitors (SECTION 7.1), but it does not explicitly state that muscle damage risk is higher solely due to high statin dose in general.
Muscle damage is more common in people taking high doses of Lipitor.
Same issue: no explicit general high-dose frequency/risk increase statement in provided excerpts.
Muscle damage is more common in people with pre-existing muscle conditions taking Lipitor.
The provided excerpts do not mention pre-existing muscle conditions as a risk factor.
Lipitor is linked to an increased risk of muscle damage and liver damage when taken with certain medications.
SECTION 7 supports increased myopathy risk with certain concomitant drugs, but the provided excerpts do not support “liver damage” risk increase with those medications.
Lipitor can interact with warfarin (Coumadin).
Warfarin is not mentioned in the provided SECTION 7 excerpts.
Lipitor can interact with erythromycin (Erythrocin).
The provided SECTION 7.1 excerpt names clarithromycin (not erythromycin) as an example of strong CYP3A4 inhibitors; erythromycin is not mentioned.
Lipitor can interact with grapefruit juice.
SECTION 7.2 supports grapefruit juice increasing plasma concentrations of atorvastatin (especially with excessive consumption). The claim is broadly supported, but the provided excerpt specifies excess (>1.2 liters/day); the broad wording without the threshold is only partially supported.
Lipitor can interact with grapefruit.
Same partial support issue as grapefruit juice: label excerpt specifically discusses grapefruit juice.
Lipitor can interact with pomegranate juice.
Pomegranate is not mentioned in the provided SECTION 7 excerpts.
Lipitor can interact with pomegranate.
Pomegranate is not mentioned in the provided SECTION 7 excerpts.
Lipitor can interact with grapefruit juice and increase the risk of side effects.
The label excerpt supports increased plasma concentrations of atorvastatin with excessive grapefruit juice; it does not explicitly state “increase the risk of side effects.”
Contradictions
Low
AI Statement
Lipitor is used to prevent heart disease.
Label Reference
SECTION 1.1 provides reductions in specific cardiovascular outcomes (e.g., MI, stroke, revascularization, angina) as indications; it does not use the general phrase “prevent heart disease.”
Important Omissions
For pregnancy-related claims: label states LIPITOR is contraindicated in women who are pregnant or may become pregnant, and may cause fetal harm (SECTION 4.3 and SECTION 8.1). The response claims caution/avoidance framing without directly stating the contraindication.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Several adverse-effect frequency assertions (“most common”) are not supported by the provided label excerpts, and some serious adverse effects (e.g., pancreatitis) are not mentioned. Pregnancy guidance is less precise than the contraindication language in the provided excerpts.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Overbroad/unsupported “most common” and “rare but serious” side-effect frequency/seriousness statements; some drug interactions and adverse events are not supported (e.g., warfarin, pomegranate, pancreatitis, erythromycin).
Suggested Improvement
Restrict adverse reaction statements to those explicitly listed in the provided excerpts (e.g., SECTION 6.1 five most common discontinuation-related adverse reactions; SECTION 6.2 postmarketing list) and avoid unsupported frequency/rarity wording. Limit interaction claims to drugs explicitly mentioned in the provided SECTION 7 excerpts, and use the exact pregnancy contraindication wording from SECTION 4.3/8.1.